LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 30

Search options

  1. Article: Tailor-made chemotherapy for cancer patients.

    van Warmerdam, L J

    The Netherlands journal of medicine

    1997  Volume 51, Issue 1, Page(s) 30–35

    Abstract: Dosages of anticancer agents are usually calculated from a uniform standard-the body surface area (BSA). Although the BSA is proportionate to many physiological functions, it is however only partially related to the overall drug clearance. Consequently, ... ...

    Abstract Dosages of anticancer agents are usually calculated from a uniform standard-the body surface area (BSA). Although the BSA is proportionate to many physiological functions, it is however only partially related to the overall drug clearance. Consequently, a wide variability in drug exposure and drug concentrations can be found between patients, by which some experience little toxicity, while others may show severe toxic symptoms. It seems clear that monitoring of plasma drug concentrations can be a useful tool to further optimize current cancer chemotherapy. The problem that pharmacokinetic parameters are usually generated from concentration-time profiles obtained after multiple venepunctures can be reduced by applying limited sampling models (LSM). Other tailor-made dosing strategies include the Calvert formula for carboplatin dosing and strategies based on the characteristics of the individual patient. It can be concluded that the determination of pharmacokinetic parameters and adjustment of the drug dose in each patient to a predefined 'target' value with an optimal therapeutic outcome, could contribute substantially to improvement of current chemotherapeutic treatment.
    MeSH term(s) Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/therapeutic use ; Body Surface Area ; Dose-Response Relationship, Drug ; Humans ; Neoplasms/drug therapy ; Neoplasms/metabolism ; Treatment Outcome
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 1997-07
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 193149-0
    ISSN 1872-9061 ; 0300-2977
    ISSN (online) 1872-9061
    ISSN 0300-2977
    DOI 10.1016/s0300-2977(97)00033-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 576: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Panitumumab monotherapy as a second-line treatment in metastasised colorectal cancer: a single centre experience.

    van Hellemond, I E G / Creemers, G J / van Warmerdam, L J C / de Jong, F A / Koornstra, R H T

    Clinical oncology (Royal College of Radiologists (Great Britain))

    2014  Volume 26, Issue 3, Page(s) 135–141

    Abstract: Aims: To report our clinical experience of panitumumab monotherapy as a second-line treatment for patients with metastatic colorectal cancer (mCRC).: Materials and methods: This retrospective, descriptive study included a series of consecutive ... ...

    Abstract Aims: To report our clinical experience of panitumumab monotherapy as a second-line treatment for patients with metastatic colorectal cancer (mCRC).
    Materials and methods: This retrospective, descriptive study included a series of consecutive patients receiving panitumumab monotherapy (6 mg/kg 2 weekly) at a single centre in the Netherlands between June 2009 and November 2011. All patients had wild-type KRAS tumours, had progressed during first-line fluoropyrimidine-based therapy and were not candidates for, or refused, standard second-line therapy (usually irinotecan in the Netherlands). Prophylactic medication was given for epidermal growth factor receptor inhibitor-associated skin toxicities.
    Results: Thirty-one patients were treated during this period. The most commonly administered first-line mCRC regimen was capecitabine/oxaliplatin/bevacizumab (18/31 patients; 58.1%). Patients received a mean of 7.9 (range 1-18) panitumumab cycles. The median progression-free survival was 3.4 (95% confidence interval 2.4, 4.4) months. The median overall survival estimates were 11.4 (95% confidence interval 1.2, 21.6) months from the initiation of panitumumab monotherapy. Ten patients experienced partial responses according to Response Evaluation Criteria In Solid Tumors (RECIST; objective response rate: 32.3%); disease was controlled (objective response or stable disease) in 15 patients (48.4%). Carcinoembryonic antigen (CEA) responses (two consecutive ≥10% decreases from baseline) occurred in 11/29 patients (37.9%); all of whom had >50% decreases in CEA levels. All patients with an objective response at week 12 had CEA reductions at weeks 6 and 12. The only adverse events were grade 1/2 skin toxicities (61.3%) and gastrointestinal complaints (6.5%); three other patients (9.7%) experienced both skin and gastrointestinal complaints.
    Conclusion: Panitumumab monotherapy seems to be a safe and active second-line treatment for patients with wild-type KRAS mCRC, with activity in line with that seen for irinotecan monotherapy, but with less toxicity. CEA may provide a useful early indicator of response to panitumumab.
    MeSH term(s) Aged ; Antibodies, Monoclonal/administration & dosage ; Antineoplastic Agents/administration & dosage ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Humans ; Male ; Neoplasm Metastasis ; Retrospective Studies
    Chemical Substances Antibodies, Monoclonal ; Antineoplastic Agents ; panitumumab (6A901E312A)
    Language English
    Publishing date 2014-03
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1036844-9
    ISSN 1433-2981 ; 0936-6555
    ISSN (online) 1433-2981
    ISSN 0936-6555
    DOI 10.1016/j.clon.2013.10.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2774: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer.

    Vriens, B E P J / Vriens, I J H / Aarts, M J B / van Gastel, S M / van den Berkmortel, F W P J / Smilde, T J / van Warmerdam, L J C / van Spronsen, D J / Peer, P G M / de Boer, M / Tjan-Heijnen, V C G

    Breast cancer research and treatment

    2017  Volume 165, Issue 3, Page(s) 593–600

    Abstract: Purpose: The INTENS study was designed to determine whether delivering neoadjuvant chemotherapy at a higher dose in a shorter period of time improves outcome of breast cancer patients.: Methods: Women with newly diagnosed breast cancer were randomly ... ...

    Abstract Purpose: The INTENS study was designed to determine whether delivering neoadjuvant chemotherapy at a higher dose in a shorter period of time improves outcome of breast cancer patients.
    Methods: Women with newly diagnosed breast cancer were randomly assigned to neoadjuvant chemotherapy consisting of four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel (AC 60/600-T 100 mg/m
    Results: In total, 201 patients were included. The pCR rates were 28% for patients treated with AC-T and 19% for patients treated with TAC, with an odds ratio of 1.60 (95% CI 0.90-3.21). With a median follow-up of 6 years (range 0.04-8.41 years), the five-year disease-free survival was 81% for patients treated with sequentially AC-T and 71% for patients treated with concurrent triplet TAC chemotherapy with a stratified hazard ratio (HR) of 0.50 (95% CI 0.29-0.86). Five-year overall survival was 84% versus 76%, respectively, with a stratified HR of 0.55 (95% CI 0.29-1.03).
    Conclusions: No differences were observed between the two treatment arms with respect to pCR rate, but the sequentially delivered chemotherapy outperformed the triplet combination chemotherapy in terms of survival, despite a lower cumulative dose per agent. GOV nr NCT00314977.
    MeSH term(s) Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor ; Breast Neoplasms/drug therapy ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Female ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Survival Analysis ; Treatment Outcome ; Young Adult
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2017-07-03
    Publishing country Netherlands
    Document type Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 604563-7
    ISSN 1573-7217 ; 0167-6806
    ISSN (online) 1573-7217
    ISSN 0167-6806
    DOI 10.1007/s10549-017-4364-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1655: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.

    Vriens, B E P J / Aarts, M J B / de Vries, B / van Gastel, S M / Wals, J / Smilde, T J / van Warmerdam, L J C / de Boer, M / van Spronsen, D J / Borm, G F / Tjan-Heijnen, V C G

    European journal of cancer (Oxford, England : 1990)

    2013  Volume 49, Issue 15, Page(s) 3102–3110

    Abstract: Background: This study was designed to determine whether delivering neo-adjuvant chemotherapy at a higher dose in a shorter period of time improves outcome of breast cancer patients.: Patients and methods: Women with newly diagnosed breast cancer ... ...

    Abstract Background: This study was designed to determine whether delivering neo-adjuvant chemotherapy at a higher dose in a shorter period of time improves outcome of breast cancer patients.
    Patients and methods: Women with newly diagnosed breast cancer were randomly assigned to neoadjuvant chemotherapy of four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel (AC 60/600 - T 100 mg/m(2)) or six cycles of TAC (75/50/500 mg/m(2)) every 3 weeks. The primary endpoint was the pathologic complete response (pCR) rate, defined as no invasive tumour present in the breast.
    Results: In total, 201 patients were included. Baseline characteristics were well balanced. AC-T resulted in pCR in 21% and TAC in 16% of patients (odds ratio 1.44 (95% confidence interval (CI) 0.67-3.10). AC-T without primary granulocyte-colony stimulating factor (G-CSF) prophylaxis was associated with more febrile neutropenia compared to TAC with primary G-CSF prophylaxis (23% versus 9%), and with more grade 3/4 sensory neuropathy (5% versus 0%).
    Conclusions: With a higher cumulative dose for the concurrent arm, no differences were observed between the two treatment arms with respect to pCR rate. The differential toxicity profile could partly be explained by different use of primary G-CSF prophylaxis.
    MeSH term(s) Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Chemotherapy, Adjuvant ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Drug Administration Schedule ; Female ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Survival Rate ; Taxoids/administration & dosage ; Taxoids/adverse effects ; Young Adult
    Chemical Substances Taxoids ; docetaxel (15H5577CQD) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P)
    Language English
    Publishing date 2013-10
    Publishing country England
    Document type Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2013.06.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Identification of residual breast tumour localization after neo-adjuvant chemotherapy using a radioactive 125 Iodine seed.

    van Riet, Y E A / Maaskant, A J G / Creemers, G J / van Warmerdam, L J C / Jansen, F H / van de Velde, C J H / Rutten, H J T / Nieuwenhuijzen, G A P

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

    2010  Volume 36, Issue 2, Page(s) 164–169

    Abstract: Introduction: The use of neo-adjuvant chemotherapy has increased in the treatment of loco-regionally advanced primarily operable breast cancer. As a result of improved neo-adjuvant chemotherapy regimes the number of clinical as well as radiological ... ...

    Abstract Introduction: The use of neo-adjuvant chemotherapy has increased in the treatment of loco-regionally advanced primarily operable breast cancer. As a result of improved neo-adjuvant chemotherapy regimes the number of clinical as well as radiological responses have increased. In case of a complete response it is difficult to identify residual disease and to perform an adequate radical breast-conserving surgery. Therefore localization of the original tumour bed is mandatory. In this study we propose a novel technique with a seed containing radioactive 125 Iodine ((125)I). The (125)I has a half-time of 60 days and is therefore still recognisable with a gamma probe after admittance of several courses of neo-adjuvant chemotherapy.
    Material and methods: In the period from July 2003 and November 2008, 47 consecutive patients had successful (125)I seed localization of a breast tumour before starting neo-adjuvant chemotherapy.
    Results: The overall clinical response rate to neo-adjuvant chemotherapy was 100%. Complete clinical response occurred in 34 patients, partial clinical response occurred in 13 patients. Complete radiological response occurred in 18 patients, partial radiological response occurred in 29 patients. The initial surgical treatment consisted of breast-conserving surgery for all 47 patients, after a mean of 170 days (range: 70-220) after (125)I seed localization. In 19 patients pathology revealed no residual tumour, 23 patients showed a partial response. Only 3 lumpectomies were irradical.
    Conclusion: This study has shown that (125)I seed localization is a novel and highly successful technique in localizing the tumour bed in patients who receive neo-adjuvant chemotherapy for breast cancer leading to a high percentage of radical margins in case of breast-conserving surgery.
    MeSH term(s) Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/diagnostic imaging ; Breast Neoplasms/drug therapy ; Combined Modality Therapy ; Female ; Humans ; Iodine Radioisotopes ; Mastectomy, Segmental ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm, Residual/diagnosis ; Radioimmunodetection ; Radiopharmaceuticals
    Chemical Substances Iodine Radioisotopes ; Radiopharmaceuticals
    Language English
    Publishing date 2010-02
    Publishing country England
    Document type Journal Article
    ZDB-ID 632519-1
    ISSN 1532-2157 ; 0748-7983
    ISSN (online) 1532-2157
    ISSN 0748-7983
    DOI 10.1016/j.ejso.2009.10.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1149: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 549: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Changes in body weight during various types of chemotherapy in breast cancer patients

    Winkels, R.M. / Beijer, S. / van Lieshout, R. / van Barneveld, D. / Hofstede, J. / Kuiper, J. / Vreugdenhil, A. / van Warmerdam, L.J.C. / Schep, G. / Blaisse, R. / van Voorthuizen, T. / van Halteren, H. / Kampman, E.

    e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism

    2014  Volume 9, Issue 1

    Abstract: Background & aims Weight gain is a common problem for breast cancer patients treated with chemotherapy. It increases the risk of several comorbidities and possibly cancer recurrence. We assessed whether weight gain depends on the type of chemotherapy. ... ...

    Abstract Background & aims Weight gain is a common problem for breast cancer patients treated with chemotherapy. It increases the risk of several comorbidities and possibly cancer recurrence. We assessed whether weight gain depends on the type of chemotherapy. Methods In a retrospective study among 739 breast cancer patients, we assessed whether change in body weight during chemotherapy differed between types of chemotherapy. Information about weight, clinical and personal factors was retrieved from medical records of breast cancer patients treated with chemotherapy between 2001 and 2010 in 4 different hospitals. Results Body weight information was complete in n = 483 patients (66%). There was substantial between-patients variability in weight change during chemotherapy: within the upper quintile of weight change, median weight gain was +6 kg, while in the bottom quintile median weight loss was of -3 kg. Adjusted multivariate regression analysis showed that change in weight differed between types of chemotherapy: women treated with anthracyclines + taxanes gained +0.9 kg (95%CI 0.1, 1.7) more than women treated with anthracyclines only. This differential change in weight was no longer statistically significant after taking into account that regimens with anthracyclines + taxanes have a longer duration than regimens with anthracyclines only. Conclusion There was more weight gain among patients treated with anthracyclines + taxanes than among patients treated with anthracyclines-only. This is partly explained by the longer duration of regimes with anthracyclines + taxanes.
    Keywords Adjuvant chemotherapy ; Body weight ; Breast cancer ; Weight gain
    Subject code 610
    Language English
    Publishing country nl
    Document type Article ; Online
    ISSN 1751-4991
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article: Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.

    Nannan Panday, V R / van Warmerdam, L J / Huizing, M T / Ten Bokkel Huinink, W W / Vermorken, J B / Giaccone, G / Veenhof, C H / Schellens, J H / Beijnen, J H

    Clinical drug investigation

    2008  Volume 15, Issue 4, Page(s) 327–335

    Abstract: Carboplatin is a frequently used antitumour agent recommended to be administered according to the Calvert formula: dose = AUC x (GFR+25), where GFR is the glomerular filtration rate as measured by (51)Cr-EDTA clearance and AUC is the targeted area under ... ...

    Abstract Carboplatin is a frequently used antitumour agent recommended to be administered according to the Calvert formula: dose = AUC x (GFR+25), where GFR is the glomerular filtration rate as measured by (51)Cr-EDTA clearance and AUC is the targeted area under the carboplatin concentration versus time curve. In several modified Calvert formulae, the GFR is estimated on the basis of serum creatinine levels. We compared AUCs of carboplatin that were predicted by modified Calvert formulae with actual measured AUCs in 75 courses in patients with non-small cell lung cancer or ovarian cancer who were treated with the combination of carboplatin-paclitaxel. Predictions were made using two modified Calvert formulae, in which the GFR was calculated by serum creatinine level-based equations, according to Jelliffe (Eq. 1) and Cockroft-Gault (Eq. 2). We also studied the performance of a formula for the clearance of carboplatin, as proposed by Chatelut (Eq. 3). The actual measured mean AUC was 4.6 mg/ml.min (range 1.9 to 10.4 mg/ml.min, SD 1.7). Equation 1 overestimated the AUC by 32.9% with an imprecision of 43.0%, and equation 2 overestimated the AUC by 27.6% with an imprecision of 33.4%. For equation 3, an AUC overestimation of only 10.2%, but with an imprecision of 25.3%, was observed. In conclusion, all three equations overestimated the carboplatin AUCs and had poor precisions. We concluded that the real carboplatin AUCs were lower than calculated, using the three tested formulae. This may have important consequences for ongoing and future phase II and III studies with carboplatin-paclitaxel combinations, utilising these formulae to calculate the carboplatin dose. Thus far, the original Calvert dosage formula remains the 'golden standard'.
    Language English
    Publishing date 2008-03-28
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 1220136-4
    ISSN 1179-1918 ; 1173-2563 ; 0114-2402
    ISSN (online) 1179-1918
    ISSN 1173-2563 ; 0114-2402
    DOI 10.2165/00044011-199815040-00009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2807: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: An overview of the clinical pharmacology of topotecan.

    Dennis, M J / Beijnen, J H / Grochow, L B / van Warmerdam, L J

    Seminars in oncology

    1997  Volume 24, Issue 1 Suppl 5, Page(s) S5–12–S5–18

    Abstract: Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a topoisomerase I inhibitor, is a semisynthetic camptothecin that has been structurally modified for increased water solubility. The closed lactone ring predominates at acidic pH, ...

    Abstract Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a topoisomerase I inhibitor, is a semisynthetic camptothecin that has been structurally modified for increased water solubility. The closed lactone ring predominates at acidic pH, but the reverse reaction of the parent into the metabolite predominates at physiologic pH. The pharmacokinetic profile of topotecan is usually characterized by a two-compartment model and is linear in the dose range of 0.5 to 3.5 mg/m2. Following intravenous administration for 5 days at doses of 0.5 to 1.5 mg/m2/d as a 30-minute infusion, topotecan has a volume of distribution of approximately 130 L. Mean plasma clearance for topotecan (total) was approximately 1,000 mL/min with a plasma half-life of 2 to 3 hours. Renal clearance is an important determinant of topotecan elimination, with approximately 30% of the dose excreted in the urine. In three phase I studies in which the schedule of five daily doses every 21 or 28 days was investigated, all found 1.5 mg/m2/d to be the maximum tolerated dose. Neutropenia (reversible and noncumulative over time) was the major dose-limiting toxicity; fevers and infections were infrequently reported. The magnitude of topotecan exposure was correlated to the observed myelosuppression.
    MeSH term(s) Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/pharmacology ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Camptothecin/analogs & derivatives ; Camptothecin/chemistry ; Camptothecin/pharmacokinetics ; Camptothecin/pharmacology ; Chemical Phenomena ; Chemistry, Physical ; Clinical Trials, Phase I as Topic ; Dose-Response Relationship, Drug ; Enzyme Inhibitors/administration & dosage ; Enzyme Inhibitors/adverse effects ; Enzyme Inhibitors/chemistry ; Enzyme Inhibitors/pharmacokinetics ; Enzyme Inhibitors/pharmacology ; Female ; Half-Life ; Humans ; Hydrogen-Ion Concentration ; Infusions, Intravenous ; Lactones/chemistry ; Metabolic Clearance Rate ; Models, Chemical ; Neutropenia/chemically induced ; Solubility ; Topoisomerase I Inhibitors ; Topotecan ; Water
    Chemical Substances Antineoplastic Agents ; Enzyme Inhibitors ; Lactones ; Topoisomerase I Inhibitors ; Water (059QF0KO0R) ; Topotecan (7M7YKX2N15) ; Camptothecin (XT3Z54Z28A)
    Language English
    Publishing date 1997-02
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 189220-4
    ISSN 1532-8708 ; 0093-7754
    ISSN (online) 1532-8708
    ISSN 0093-7754
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1348: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.

    van Warmerdam, L J / Rodenhuis, S / van Tellingen, O / Maes, R A / Beijnen, J H

    Cancer chemotherapy and pharmacology

    1994  Volume 35, Issue 2, Page(s) 179–181

    Abstract: A limited sampling model for the estimation of the carboplatin area under the concentration versus time curve (AUC), as developed by Sørensen et al., was validated prospectively for the use in a high-dose combination chemotherapy schedule. The model ... ...

    Abstract A limited sampling model for the estimation of the carboplatin area under the concentration versus time curve (AUC), as developed by Sørensen et al., was validated prospectively for the use in a high-dose combination chemotherapy schedule. The model allows an estimation of the AUC on the basis of only one timed plasma drug concentration, sampled at exactly 2.75 h after a 1-h carboplatin infusion. Pharmacokinetic curves were obtained from nine patients receiving carboplatin (400 mg/m2 per day) combined with cyclophosphamide (1500 mg/m2 per day), thiotepa (120 mg/m2 per day), and mesna (3 g/day) for 4 consecutive days. Peripheral blood stem-cell transplantation (PBSCT) was performed 3 days later to restore hematopoiesis. Using this combination of high doses, the model proved to be unbiased (MPE -3.40%; SE, 1.22%) and highly precise [root mean squared prediction error (RMSE), 5.15%; SE, 0.17%] for estimation of the AUC during 4 consecutive days. The validated limited sampling model provides a starting point for future pharmacokinetic studies in a larger population of patients, which might lead to more insight into the relationships with the pharmacodynamic outcome of carboplatin and may help in achieving more rational dosing of patients on the basis of an AUC determination.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/blood ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Carboplatin/administration & dosage ; Carboplatin/blood ; Carboplatin/pharmacokinetics ; Cyclophosphamide/administration & dosage ; Drug Administration Schedule ; Hematopoietic Stem Cell Transplantation ; Humans ; Infusions, Intravenous ; Mesna/administration & dosage ; Models, Biological ; Reproducibility of Results ; Thiotepa/administration & dosage
    Chemical Substances Cyclophosphamide (8N3DW7272P) ; Thiotepa (905Z5W3GKH) ; Carboplatin (BG3F62OND5) ; Mesna (NR7O1405Q9)
    Language English
    Publishing date 1994
    Publishing country Germany
    Document type Clinical Trial ; Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 6820-2
    ISSN 1432-0843 ; 0344-5704 ; 0943-9404
    ISSN (online) 1432-0843
    ISSN 0344-5704 ; 0943-9404
    DOI 10.1007/BF00686644
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1420: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Limited-sampling models for anticancer agents.

    van Warmerdam, L J / ten Bokkel Huinink, W W / Maes, R A / Beijnen, J H

    Journal of cancer research and clinical oncology

    1994  Volume 120, Issue 7, Page(s) 427–433

    Abstract: Pharmacokinetic parameters of antineoplastic drugs are usually generated from concentration/time profiles obtained after multiple venipunctures. With limited-sampling models (LSM) this number can be reduced to between one and three timed plasma samples. ... ...

    Abstract Pharmacokinetic parameters of antineoplastic drugs are usually generated from concentration/time profiles obtained after multiple venipunctures. With limited-sampling models (LSM) this number can be reduced to between one and three timed plasma samples. LSMs may facilitate population pharmacokinetic/pharmacodynamic studies, which eventually may lead to a dosing strategy based on the characteristics of the individual patient. In this article, the development, validation and application of several LSMs reported in the literature are reviewed.
    MeSH term(s) Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacokinetics ; Drug Administration Schedule ; Models, Biological ; Sampling Studies ; Statistics as Topic
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 1994
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 134792-5
    ISSN 1432-1335 ; 0171-5216 ; 0084-5353 ; 0943-9382
    ISSN (online) 1432-1335
    ISSN 0171-5216 ; 0084-5353 ; 0943-9382
    DOI 10.1007/bf01240143
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.10: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top